ArticleScientific reports2025
Low-normal free thyroxine is associated with a higher prevalence of lower extremity arterial disease in euthyroid type 2 diabetes mellitus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggest that high-normal concentrations of free triiodothyronine (FT3) were associated with a lower prevalence of microangiopathy in adult euthyroid people with type 1 diabetes. This study was performed to identify the association between thyroid hormones and lower extremity arterial disease (LEAD) in euthyroid patients with type 2 diabetes mellitus (T2DM). A total of 1052 euthyroid T2DM patients were enrolled, including 704 patients with LEAD as observation group and 348 patients with T2DM alone as control group. The differences in clinical characteristics, biochemical indexes, thyroid hormone between the two groups were compared. At the same time, the association between the incidence of LEAD and thyroid hormone was analyzed. The data demonstrated that FT4 levels were significantly lower in the LEAD patients than in the without LEAD patients (16.1 vs. 16.5 pmol/L). The logistic regression analysis revealed that free thyroxine (FT4) was significantly associated with the incidence of LEAD in T2DM patients, and the prevalence of LEAD increased gradually from the highest FT4 quartile to the lowest FT4 quartile (P < 0.05). In conclusion, patients with low-normal FT4 had a higher prevalence of diabetic LEAD, suggesting that adjusting FT4 levels may better regulate metabolism and thus reduce lower extremity arterial injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.